Valproic acid does not affect markers of human immunodeficiency virus disease progression.
Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells. This retrospective case-control study (n = 30) examined effects of VPA on markers of HIV progression. VPA was not associated with changes in cerebrospinal fluid viral loads (VL), plasma VL, or neuropsychological performance. VPA patients had a trend towards lower CD4+ cells (P = .08) at follow-up. Concurrent antiretrovirals did not alter these relationships. VPA does not induce viremia or promote disease progression and may be safe for clinical intervention.
Ances
Beau M
BM
Department of Neurosciences, University of California, San Diego, California, USA. bances@ucsd.edu
Letendre
Scott
S
Buzzell
Maria
M
Marquie-Beck
Jennifer
J
Lazaretto
Deborah
D
Marcotte
Thomas D
TD
Grant
Igor
I
Ellis
Ronald J
RJ
D000328:Adult; D000927:Anticonvulsants / Q000494:pharmacology*; D015415:Biomarkers / Q000032:analysis*; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018450:Disease Progression; D005260:Female; D006678:HIV / Q000235:genetics / Q000302:isolation & purification; D015658:HIV Infections / Q000503:physiopathology*; D006801:Humans; D008297:Male; D014635:Valproic Acid / Q000494:pharmacology*; D019562:Viral Load
D000927:Anticonvulsants; D015415:Biomarkers; D014635:Valproic Acid